US Edition
Agnostic dMMR tumour PD-1 inhibitor approach may avoid resection
Summary by medwirenews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Agnostic dMMR tumour PD-1 inhibitor approach may avoid resection
By Lynda Williams, medwireNews ReportermedwireNews: Patients with deficient mismatch repair cancers may not require surgery after 6 months of neoadjuvant treatment with the PD-1 inhibitor dostarlimab, suggests research published in The New England Journal of Medicine.This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.Read the full story on the L’Institut Servier websiteImage credit: © bymu…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
